Matinas BioPharma's Lead Antifungal Product Candidate MAT2203 Granted QIDP and Fast Track Designations for Prophylaxis of Invasive ...
- Third QIDP Designation Granted by FDA for MAT2203 – - Phase 2a study enrollment underway to evaluate MAT2203 for the treatment of chronic mucocutaneous candidiasis at NIH/NIAID - BEDMINSTER, N.J., Sept. 07, 2016 (GLOBE NEWSWIRE) -- Matinas BioPharma …